These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25561485)

  • 21. The re-emergence of hallucinogenic research.
    Begola MJ; Dowben JS
    Perspect Psychiatr Care; 2018 Oct; 54(4):523-526. PubMed ID: 29464720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. News Brief: MDMA therapy for PTSD.
    Am J Nurs; 2023 Dec; 123(12):10. PubMed ID: 37988009
    [No Abstract]   [Full Text] [Related]  

  • 23. Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.
    Szafoni S; Więckiewicz G; Pudlo R; Gorczyca P; Piegza M
    Psychiatr Pol; 2022 Aug; 56(4):823-836. PubMed ID: 37074831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in service personnel.
    Cipriani A; Cowen PJ
    Lancet Psychiatry; 2018 Jun; 5(6):453-455. PubMed ID: 29728332
    [No Abstract]   [Full Text] [Related]  

  • 25. Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.
    Herpers J; Maximets N; van Dongen NNN; Zijlmans J; Vermetten E
    Eur J Psychotraumatol; 2024; 15(1):2378651. PubMed ID: 39113624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDMA Therapy for PTSD: Inching Closer to-or Farther From-Approval?
    Davitian L
    Sr Care Pharm; 2024 Aug; 39(8):311-314. PubMed ID: 39080866
    [No Abstract]   [Full Text] [Related]  

  • 27. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
    Verheyden SL; Maidment R; Curran HV
    J Psychopharmacol; 2003 Dec; 17(4):371-8. PubMed ID: 14870948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDMA (Ecstacy): useful information for health professionals involved in drug education programs.
    Elk C
    J Drug Educ; 1996; 26(4):349-56. PubMed ID: 9071057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.
    Parrott AC
    Psychopharmacology (Berl); 2007 Apr; 191(2):181-93. PubMed ID: 17297639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premise, promise and challenges of MDMA assisted therapy for PTSD.
    Madero S; Alvarez OD
    Eur Neuropsychopharmacol; 2023 May; 70():19-20. PubMed ID: 36806884
    [No Abstract]   [Full Text] [Related]  

  • 31. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.
    Cohen IV; Makunts T; Abagyan R; Thomas K
    Sci Rep; 2021 Mar; 11(1):5997. PubMed ID: 33727616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDMA-assisted therapy for PTSD passes phase III trial.
    Mullard A
    Nat Rev Drug Discov; 2023 Nov; 22(11):863. PubMed ID: 37803082
    [No Abstract]   [Full Text] [Related]  

  • 33. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
    Haridy R
    Nature; 2023 Jul; 619(7969):227-228. PubMed ID: 37386185
    [No Abstract]   [Full Text] [Related]  

  • 34. Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
    Nogrady B
    BMJ; 2023 Jul; 382():1599. PubMed ID: 37433614
    [No Abstract]   [Full Text] [Related]  

  • 35. [MDMA ("Ecstasy")--a dangerous drug or psychotherapeutic drug?].
    Szukaj M
    Nervenarzt; 1994 Nov; 65(11):802-5. PubMed ID: 7816160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.
    Bouso JC; Doblin R; Farré M; Alcázar MA; Gómez-Jarabo G
    J Psychoactive Drugs; 2008 Sep; 40(3):225-36. PubMed ID: 19004414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stressing the possibilities.
    Shrubb R
    Ment Health Today; 2013; ():12-3. PubMed ID: 24354215
    [No Abstract]   [Full Text] [Related]  

  • 38. The promise of 3,4-methylenedioxymethamphetamine (MDMA) in combination with prolonged exposure therapy for posttraumatic stress disorder.
    Rothbaum BO; Maples-Keller JL
    Neuropsychopharmacology; 2023 Jan; 48(1):255-256. PubMed ID: 35859012
    [No Abstract]   [Full Text] [Related]  

  • 39. Can ecstasy treat the agony of PTSD?
    Kupferschmidt K
    Science; 2014 Jul; 345(6192):22-3. PubMed ID: 24994631
    [No Abstract]   [Full Text] [Related]  

  • 40. The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study.
    Avanceña ALV; Kahn JG; Marseille E
    Clin Drug Investig; 2022 Mar; 42(3):243-252. PubMed ID: 35230652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.